Resource Centre
Discover a wealth of knowledge and insights from the experts at StarFish Medical. Our Resource Centre offers product development tips, reviews of new and cutting-edge technologies, and in-depth articles on regulatory updates and compliance in medical device development.
-
“From Scrappy Startup to Trailblazer: How Redlen is Revolutionizing CT Therapy” is now available as an on demand webinar.
-
In this episode of Bio Break, Nick and Joris dive into the fascinating realm of biosensors, showcasing how nature’s biological processes inspire groundbreaking innovations in medical device technology. From jellyfish to fireflies, the natural world has provided invaluable tools that are transforming diagnostics and research.
-
On Demand recording of Automating the pre-commercial exit as a strategy for high-value startups presented by Amr Salahieh, serial entrepreneur and founder of Sadra Medical and Shifamed, at Medical Device Playbook Newport Beach 2024 is now available for on demand viewing.
-
Drawing on their extensive experience in executive roles and high-tech M&A, the speakers delivered an engaging discussion tailored for MedTech founders and executives.
-
In this episode of Bio Break, Joris van der Heijden and Nick Allan discuss an advanced category of combination devices: drug activation devices. Unlike drug delivery devices that transport medication to specific locations, drug activation devices ensure the drug becomes active precisely where it is needed in the body, reducing systemic side effects and enhancing therapeutic effectiveness.
-
Artificial intelligence (AI) has rapidly become a transformative force across industries, but its application in medical devices presents unique challenges. In his article "A Practical Future of Developing AI for Medical Devices" for MD+DI, Thor Tronrud, a Research and Data Analysis-Focused Software Engineer at StarFish Medical, sheds light on bridging knowledge gaps, navigating regulatory constraints, and developing robust AI solutions for medical devices.
-
The U.S. Food and Drug Administration (FDA) made a significant update to its regulatory approach for in vitro diagnostic products (IVDs), including laboratory developed tests (LDTs). Detailed in a FDA Laboratory Developed Tests Policy guidance document issued on June 25, 2024.
-
Drug Delivery Solutions for Cell and Gene Therapy (CGT) Challenges explores effective delivery devices and solutions for advanced CGT therapies and their unique challenges.
-
Aerosol Drug Delivery Systems, including Aerosol-based pulmonary-delivered drug devices, offer significant value by enabling targeted drug delivery directly to the respiratory system.
